Catalyst Pharm Inc. (CPRX) 0.62 $CPRX Technical Analysis

New Post Public Reply Private Reply Replies (0) Message Board

Jun 12, 2016 at 2:21 AM

Catalyst Pharm Inc. (CPRX) 0.62 $CPRX

Technical Analysis on Drugs - Generic Equities -- Akorn, Ironwood Pharma, Catalyst Pharma, and Pacira Pharma
PR Newswire - Fri Jun 10, 7:00AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Akorn Inc. (NASDAQ: AKRX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Learn more about these stocks by accessing their free trade alerts at:
IRWD: 12.87 (-0.13), CPRX: 0.62 (-0.03), AKRX: 30.25 (-0.55), PCRX: 44.07 (-1.34)

Catalyst Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed Jun 01, 7:03AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the Company will be presenting at the Jefferies 2016 Healthcare Conference, in New York. Patrick J. McEnany, Catalyst's Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer/COO, will provide an overview of the Company and its key programs on Tuesday, June 7 at 4:30 pm ET. The Company's presentation materials will be available on the "Investors" section of the Company's website, www.catalystpharma.com following the presentation.
CPRX: 0.62 (-0.03)

Catalyst (CPRX) Resorts to Layoffs for Firdapse Development
Zacks Equity Research - Zacks Investment Research - Wed May 18, 8:22AM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) announced that it will reduce its workforce by approximately 30%. The move will primarily affect the commercial team.
ABT: 38.40 (-0.47), JNJ: 117.01 (+0.01), CPRX: 0.62 (-0.03), PFE: 35.29 (-0.02)

Catalyst Pharmaceutical's Firdapse Phase 3 Study Published in Muscle & Nerve
GlobeNewswire - Wed May 18, 7:03AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported on the publication of detailed results from the LMS-002 Phase 3 study of amifampridine phosphate (Firdapse(R)) in patients with Lambert-Eaton myasthenic syndrome (LEMS). The study results were published in the May 2016 issue of Muscle & Nerve (volume 53, number 5), authored by Dr. Shin Oh, et al.
CPRX: 0.62 (-0.03)

Catalyst Pharmaceuticals Announces Reduction in Workforce as Part of Operating Expense Management Plan
GlobeNewswire - Tue May 17, 7:03AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the company is reducing its workforce by approximately 30%. The reduction in workforce, which affects employees from Catalyst's commercial team, is part of Catalyst's ongoing efforts to conserve cash as it works to complete the requirements for an NDA submission of Firdapse(R) (amifampridine phosphate) for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS).
CPRX: 0.62 (-0.03)

Catalyst (CPRX) Posts In-Line Q1 Loss, Firdapse in Focus
Zacks Equity Research - Zacks Investment Research - Wed May 11, 2:29PM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) reported a loss of 7 cents per share in the first quarter of 2016, which was wider than the year-ago loss of 6 cents but in line with the Zacks Consensus Estimate.
ABT: 38.40 (-0.47), CPRX: 0.62 (-0.03), SHPG: 177.10 (-6.85), ARQL: 1.78 (unch)

Catalyst Pharmaceuticals Announces First Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Tue May 10, 4:10PM CDT
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported financial results for the first quarter ended March 31, 2016.
CPRX: 0.62 (-0.03)

Drug Stocks Reporting on May 10: XON, ARIA, CPRX & More
Zacks Equity Research - Zacks Investment Research - Mon May 09, 9:13AM CDT
What's in store for drug stocks, Jazz, Intrexon and others when they report their first-quarter results on May 10?
JNJ: 117.01 (+0.01), CPRX: 0.62 (-0.03), JAZZ: 150.76 (-5.26), XON: 25.27 (+0.14), AMGN: 154.78 (-2.00), ANAC: 99.17 (+0.09), ARIA: 8.27 (-0.15)

What's in the Cards for Catalyst (CPRX) in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Fri May 06, 11:18AM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) is scheduled to report first-quarter 2016 results on May 10.
IPXL: 32.45 (-1.11), CPRX: 0.62 (-0.03), JAZZ: 150.76 (-5.26), XON: 25.27 (+0.14)

Catalyst Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Wednesday, May 11th, 2016
GlobeNewswire - Fri May 06, 7:03AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that it will release First Quarter 2016 financial results after market close on Tuesday, May 10, 2016. Further, Catalyst management will host an investment-community conference call at 8:30 a.m. EDT on Wednesday, May 11, 2016 to discuss the financial results and to provide a corporate update.
CPRX: 0.62 (-0.03)

Penny Stocks To Watch on Friday April 29
ACCESSWIRE - Fri Apr 29, 11:58AM CDT
MIAMI, FL / ACCESSWIRE / April 29, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. FREEF, KEG, CPRX, and HUSA have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
CPRX: 0.62 (-0.03), KEG: 0.31 (-0.02)

The Zacks Analyst Blog Highlights: Biogen, Sarepta, Catalyst Pharmaceuticals, AbbVie and Gilead
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Sarepta, Catalyst Pharmaceuticals, AbbVie and Gilead
BIIB: 246.13 (-4.33), GILD: 84.45 (-1.32), CPRX: 0.62 (-0.03), SRPT: 19.95 (-1.04), ABBV: 61.00 (+0.25)

Biotech Stock Roundup: Biogen Tops on Q1 Earnings, Sarepta, Catalyst Plunge on Regulatory News
Arpita Dutt - Zacks Investment Research - Wed Apr 27, 3:07PM CDT
While most major biotech stocks will be reporting results this week, Biogen (BIIB) kick-started the earnings season for the sector with an earnings beat.
BIIB: 246.13 (-4.33), VRTX: 91.49 (-1.00), CPRX: 0.62 (-0.03), GILD: 84.45 (-1.32), SRPT: 19.95 (-1.04), ABBV: 61.00 (+0.25), REGN: 372.03 (-9.05)

Why Is Catyalyst Pharma (CPRX) Stock Crashing Today?
Ryan McQueeney - Zacks Investment Research - Tue Apr 26, 12:18PM CDT
Catalyst Pharmaceuticals (CPRX) stock crashed over 50% after the company announced that the FDA has requested additional data in its resubmission of a new drug application for Firdapse, a treatment for Lambert-Eaton myasthenic syndrome.
CPRX: 0.62 (-0.03)

Catalyst Pharmaceuticals Provides Regulatory Update on Firdapse
GlobeNewswire - Tue Apr 26, 5:55AM CDT
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today provided an update on the content of the planned resubmission of the New Drug Application ("NDA"

for Firdapse(R) (amifampridine phosphate), which currently has Breakthrough Therapy and Orphan Drug designations for Lambert-Eaton myasthenic syndrome (LEMS). Catalyst recently met with the Food and Drug Administration ("FDA"

to obtain greater clarity regarding what will be required by the FDA to accept the Firdapse NDA for filing.
CPRX: 0.62 (-0.03)

Catalyst (CPRX) Posts In-Line Q4 Loss, FDA Meeting in Focus
Zacks Equity Research - Zacks Investment Research - Wed Mar 16, 3:29PM CDT
Catalyst Pharmaceuticals (CPRX) reported a loss of 7 cents per share in fourth-quarter 2015, wider than the year-ago loss of 5 cents but in line with the Zacks Consensus Estimate.
CPRX: 0.62 (-0.03), SCMP: 11.70 (-0.27), CORT: 5.60 (+0.13)

Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2015 Financial Results
GlobeNewswire - Tue Mar 15, 3:30PM CDT
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported financial results for the fourth quarter and the year-ended December 31, 2015.
CPRX: 0.62 (-0.03)

What's in Store for Catalyst (CPRX) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Mar 14, 10:00AM CDT
Catalyst Pharmaceutical Partners Inc. (CPRX) is scheduled to report fourth-quarter 2015 results after the market closes on Mar 15.
ATNM: 1.82 (unch), VRX: 24.14 (-1.34), ALDX: 5.84 (-0.13), CPRX: 0.62 (-0.03)

Catalyst Pharmaceuticals to Present at the 28th Annual ROTH Conference
GlobeNewswire - Thu Mar 10, 10:55AM CST
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the Company will be presenting at the 28 Annual ROTH Conference in California. Steven Miller, Ph.D., Chief Scientific Officer/COO, will provide an overview of the Company and its key programs on Tuesday, March 15 at 9:00 am PT / 12:00 pm ET. The Company's presentation materials will be available on the "Investors" section of the Company's website, www.catalystpharma.com following the presentation.
CPRX: 0.62 (-0.03)

Catalyst Pharmaceuticals to Hold Fourth Quarter Financial Results Conference Call and Webcast on Wednesday, March 16th, 2016
GlobeNewswire - Wed Mar 09, 7:22AM CST
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that it will release Fourth Quarter and Year-End 2015 financial results after market close on Tuesday, March 15, 2016. Further, Catalyst management will host an investment-community conference call at 8:30 a.m. EDT on Wednesday March 16, 2016 to discuss the financial results and to provide a corporate update.
CPRX: 0.62 (-0.03)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rachel Noble Joins AGS: Signals Strategy Shift

A Tactical Addition to American Global Strategies The chessboard of global security just saw a savvy new player join American Global Strategies (AGS). Rachel Noble, a name that echoes through the halls of Australia's national security apparatus, has joined AGS as Senior Advisor. This isn't your garden-variety hire—this is a strategic power move. From Down Under to the...

Boosting Employability: English Skills in Italy's Job Market

Tackling Language Barriers in Italy's Workforce If you're looking to make it big in Italy, you're facing a task that demands more than just regional expertise. The working world is no longer bound by borders, and for Italians eyeing international gigs, English fluency is a must-have. While not an absolute ticket to success, grasping English could be your career's booster...

Third Lake Parts Ways with WaterView Retail Center

Third Lake Partners Exits WaterView Retail in Florida Alright, you don't stumble across deals like this every day. Third Lake Partners just tossed the keys to their WaterView Retail Center in St. Petersburg, wrapping up the retail and residential parts under one roof with Walton Street Capital. It only took a cool five years since its completion in 2021, but hey, better...

Longevity Tour Hits East Coast: Brecka's Mission

Bringing Longevity to the East Coast This weekend, something interesting is happening on the East Coast of the U.S. Gary Brecka and his Ultimate Longevity Center (ULC) are holding a series of events in Philadelphia, New York, and Boston. Everything kicks off on November 14th. If the idea of 'live longevity' leaves you scratching your head, don’t worry—I've got you...

Abbisko's PIMJETMI® Gains FDA Nod, Boosting TGCT Treatment

PIMJETMI® Scores FDA Approval, Expanding Global Reach Well, here's something to chew on over your morning coffee—PIMJETMI® (pimicotinib) just snagged the U.S. FDA's blessing to treat tenosynovial giant cell tumor (TGCT), making it another notch on Abbisko Therapeutics' belt. This approval is a strategic home run for Abbisko and their pals at Merck KGaA, Darmstadt,...

Creative Solutions Joins FICO Marketplace, Boosts AI Edge

Creative Solutions and FICO Unite Well, we're diving into some strategic magic today. Creative Solutions International, not just your average marketing agency, has just hopped onto the FICO Marketplace platform. The word on the street is they're shaking things up with their Collections Marketing Platform. It's like giving your old financial letters a whole AI-driven paint...

Envista's $430M Senior Notes: A Market Move Decoded

Envista on the Move with $430M Notes Ever feel like the market's a bit like a rollercoaster with no brakes? That's kind of where we're at with Envista Holdings Corporation (NYSE: NVST) rolling out this new financial play. They just priced a hefty $430 million in Senior Notes at a solid 6.250% due 2033. In terms of the investment world, that's a pretty big splash. The...

McEwen Faces Investigation Amid Declining Production

MUX Investors on Alert as Legal Stakes Rise The gold mining world isn't exactly flooded with excitement these days, and McEwen Inc.'s (NYSE: MUX) latest dealings ain't doing much to brighten up the scenery. When their third-quarter gold output took a nosedive—a 23% drop to be exact—it caught more eyes than a bull market will. Production Guidance in Question Now,...

Kemin Unveils LYSOFORTE ENFUSIO at EuroTier 2026

Rollin' up to EuroTier 2026 with all its buzz—a place where big players in livestock production flex their muscles—Kemin Industries dropped a new ace in the feed deck: LYSOFORTE ENFUSIO. They're betting this bad boy will shake things up for poultry and pig nutritionists looking to maximize what's already on their plate without piling on more grain or feed costs....

A Gentle Stake: Colts Neck's Rural Fight Ahead

By Ryan Hughes Updated Nov 10, 2026 Category News Views 101

Michael Fazio's Gambit in Colts Neck If you're not fired up about land deals, you should be now. Michael Fazio, the owner of Synergy Stables in Colts Neck, New Jersey, is laying his cards on the table with a proposition for preserving the integrity of the township's rural landscape. Rather than cashing in on monstrous offers for high-density housing, Fazio's plan involves...